Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 3
1 (33.3%)A Study of RX-10045 in the Treatment of Dry Eye Disease
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01675570
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Vehicle for RX-10045 arm
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01639846
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Phase 3
Completed
- Conditions
- Amyloidosis
- Interventions
- Drug: PlaceboDrug: KIACTA (eprodisate disodium)
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 261
- Registration Number
- NCT01215747
- Locations
- 🇺🇸
Raffi Minasian MD a Medical Corporation, Glendale, California, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
News
No news found